GE HealthCare adds AT&T CFO Pascal Desroches to board
GE HealthCare is adding AT&T CFO Pascal Desroches to its Board in early 2027, strengthening financial and governance expertise as the company pursues its precision care strategy.
Rhea-AI Filing Summary
GE HealthCare Technologies Inc. (GEHC) announced that its Board of Directors has appointed Pascal Desroches to serve as a director, effective January 4, 2027. He will also join the Board’s Audit Committee and the Talent, Culture, and Compensation Committee on that date.
Desroches is Senior Executive Vice President and Chief Financial Officer of AT&T and plans to retire from AT&T on December 31, 2026. He brings more than 30 years of leadership experience in finance, governance, and large-scale technology and digital transformation, including prior roles at WarnerMedia, Turner Broadcasting, KPMG, the U.S. Securities and Exchange Commission, Honeywell Aerospace, the Federal Reserve Bank of Dallas, and DaVita. As a non-employee director, he will receive compensation under GE HealthCare’s existing non-employee director compensation program and will enter into the company’s standard indemnification agreement.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective date of Board appointment: January 4, 2027
Retirement date from AT&T: December 31, 2026
Years of leadership experience: More than 30 years
+3 more
6 metrics
Effective date of Board appointment
January 4, 2027
Date Pascal Desroches becomes a GE HealthCare director and committee member
Retirement date from AT&T
December 31, 2026
Planned retirement date for Pascal Desroches as CFO of AT&T
Years of leadership experience
More than 30 years
Leadership experience of Pascal Desroches across finance, governance, and technology
Business size
$20.6 billion
Described size of GE HealthCare’s business
Number of colleagues
Approximately 54,000
GE HealthCare workforce as described in the exhibit
Par value of common stock
$0.01 per share
Par value of GE HealthCare common stock listed on Nasdaq
Key Terms
Regulation FD, indemnification agreement, Fortune 50, precision care, +2 more
6 terms
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure. On September 22, 2026, the Company issued"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
indemnification agreement regulatory
"The Company will also enter into an indemnification agreement with Mr. Desroches."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Fortune 50 financial
"Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company,"
The Fortune 50 are the 50 largest U.S. companies ranked by annual revenue on Fortune magazine’s broader Fortune 500 list. For investors, inclusion signals very large scale, broad market influence, and typically greater access to capital and resources — similar to being at the top of a leaderboard — but it does not guarantee superior stock performance, profitability, or growth prospects. Size can mean stability but also greater regulatory and competitive scrutiny.
precision care medical
"as we execute on our strategy to advance precision care, accelerate our"
Precision care is healthcare tailored to an individual’s unique biology, lifestyle and test results so treatments and prevention are chosen to work best for that specific person rather than using one-size-fits-all approaches. For investors, it matters because targeted therapies and diagnostics can raise the chance of successful outcomes, reduce wasted spending, enable premium pricing and create niche markets — think of a tailored suit versus off-the-rack clothing, where better fit can command higher value and loyalty.
pharmaceutical diagnostics medical
"provider of advanced medical technology, pharmaceutical diagnostics, and AI,"
Item 404(a) of Regulation S-K regulatory
"no transactions between Mr. Desroches and the Company that would be reportable under Item 404(a)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GEHC announce in this 8-K filing?
GE HealthCare announced that Pascal Desroches, Senior Executive Vice President and CFO of AT&T, has been appointed to its Board of Directors, effective January 4, 2027, and will serve on the Audit Committee and the Talent, Culture, and Compensation Committee.
When will Pascal Desroches join the GEHC Board and its committees?
Pascal Desroches will join the GE HealthCare Board on January 4, 2027. On that same date, he will become a member of the Board’s Audit Committee and the Talent, Culture, and Compensation Committee.
What is Pascal Desroches’ current role and when is he retiring from AT&T?
Pascal Desroches is currently Senior Executive Vice President and Chief Financial Officer of AT&T. He has served as AT&T’s CFO since 2021 and plans to retire from AT&T on December 31, 2026.
How will Pascal Desroches be compensated as a GEHC director?
Upon joining the Board, Pascal Desroches will receive compensation in accordance with GE HealthCare’s compensation program for non-employee directors, as described in the company’s Definitive Proxy Statement filed on March 19, 2026.
Will GEHC enter into any specific agreement with Pascal Desroches?
GE HealthCare will enter into its standard indemnification agreement with Pascal Desroches. The form of this agreement is the same as that filed as Exhibit 10.3 to the company’s Annual Report on Form 10-K filed on February 4, 2026.
How large is GE HealthCare’s business as described in the 8-K exhibit?
The exhibit describes GE HealthCare as a $20.6 billion business with approximately 54,000 colleagues, providing advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions across several healthcare segments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 22, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||||||||||||||
(Registrant’s telephone number, including area code) (833 ) 735-1139
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). | ||||||||
| Emerging growth company | ||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 22, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027.
Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches. The form of indemnification agreement is included as Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed with the SEC on February 4, 2026.
There is no arrangement or understanding between Mr. Desroches and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Desroches and the Company that would be reportable under Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On September 22, 2026, the Company issued a press release announcing the appointment of Pascal Desroches to its Board. A copy of the press release is furnished as Exhibit 99.
The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | ||||
| 99 | Press Release of GE HealthCare Technologies Inc., dated September 22, 2026. | ||||
| 104 | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GE HealthCare Technologies Inc. | ||||||||
(Registrant) | ||||||||
Date: September 22, 2026 | /s/ Frank R. Jimenez | |||||||
| Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory) | ||||||||
Exhibit 99
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors
CHICAGO, IL — September 22, 2026 — GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation.
“Pascal is a highly respected executive and accomplished financial leader whose experience spans corporate strategy, capital deployment, and investor engagement,” said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. “His perspective will further strengthen our Board as we execute on our strategy to advance precision care, accelerate our next wave of innovation, and create long-term value for patients, customers, and shareholders.”
Mr. Desroches has served as CFO of AT&T since 2021 and plans to retire from the company on December 31, 2026. Previously, he served as CFO of WarnerMedia following AT&T’s acquisition of Time Warner in 2018, overseeing financial operations, global real estate, and technology across HBO, Turner Broadcasting, and Warner Bros. As CFO of Turner Broadcasting, he played a pivotal role in the spin-off of three multi-billion-dollar subsidiaries: Time Warner Cable, AOL, and Time.
Earlier in his career, Mr. Desroches worked at KPMG and the U.S. Securities and Exchange Commission, gaining broad industry and regulatory experience. He serves on the boards of Honeywell Aerospace, where he chairs the audit committee, and the Federal Reserve Bank of Dallas. He also brings healthcare governance experience through nearly four years of service on the board of DaVita.
“As a global leader in precision care, GE HealthCare plays a critical role in shaping the future of healthcare and improving outcomes for patients worldwide,” said Pascal Desroches. “I look forward to serving on the Board and working with the management team to advance the company’s strategy, make care more personal and precise, drive growth, and create long-term value.”
Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com
GE HealthCare Media Contact:
Jennifer Fox
+1 -414530 - 3027
jennifer.r.fox@gehealthcare.com
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.